A compound of formula wherein a is an integer from 0 to 1; X is selected from the group consisting of -O- and -S-; R 1 is selected from the group consisting of C 1-4 alkyl and halogenated C 1 - 4 alkyl; b is an integer from 0 to 2; R 2 is selected from the group consisting of halogen, hydroxy, cyano, nitro, NR A R B, C 1-4 alkyl, -O-C 1-4 alkyl, -S-C 1 -4alkyl and halogenated C 1-4 alkyl; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; R 3 is selected from the group containing of hydrogen, halogen, hydroxy, - O-C 1-4 alkyl and NR C R D; wherein R C and R D are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; Y is CH and Z is CH; alternatively Y is CH and Z is N; alternatively Y is N and Z is N; Q is selected from the group consisting of -(L 1) c -(Ring A), -(L 1) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C); c is an integer from 0 to 1; L 1 is selected from the group consisting of -CH 2 -, -CH -, -CH 2 CH 2 -,-CH 2 CH 2 CH 2 -, -CH=CH-, -CH=CH-CH 2 -, -O-, -O-CH 2 -, -C -, -C -C -,-C -CH 2 -, -C -N(R 4)-, -N(R 4)-, -N(R 4)-CH 2 -, -N(R 4)-CH 2 CH 2 -, -N(R 4)- -,-N(R 4)-C -CH 2 -, -N(R 4)-C -CH 2 -CH 2 - and -N(R 4)-C -N(R 5)-; wherein R 4 and R 5 are each independently selected from the group consisting of hydrogen and C 1-2 alkyl; (Ring A) is selected from the group consisting of 3-cyano-phenyl, 3-benzimidamide, azetidin-3-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4-isopropyl-piperazin-1-yl, piperazin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 4-amino-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 4-phenyl-piperidin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, 3-amino-pyrrolidin-1-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 6-methyl-pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4yl, 1-(amino-methyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1-(amino-ethyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1,4-diazepan-1-yl, benzimidazol-5-yl, 1-methyl-benzimidazol-6-yl, 1-methyl-benzimidazol-5-yl, benzo[c][1,2,5]oxadiazol-5-yl, 2,5-diazabicyclo[2.2.1]hept-1-yl, 2,7-diazaspiro[4,4]nonan-2-yl and octahydropyrrolo[3,4-c]pyrrol-2-yl; (Ring B) is selected from the group consisting of phenyl and 4 to 10 membered, nitrogen containing ring structure; (Ring C) is selected from the group consisting of 4 to 10 membered, nitrogen containing ring structure; wherein (Ring C) is optionally substituted with one to two substituents independently selected from the group consisting C 1 - 4 alkyl; or a pharmaceutically acceptable salt thereof wherein said compound of formula does not have the following structure: a is an integer from 0 to 1; X is selected from the group consisting of -O- and -S-; R 1 is selected from the group consisting of C 1-4 alkyl and halogenated C 1 - 4 alkyl; b is an integer from 0 to 2; R 2 is selected from the group consisting of halogen, hydroxy, cyano, nitro, NR A R B, C 1-4 alkyl, -O-C 1-4 alkyl, -S-C 1 -4alkyl and halogenated C 1-4 alkyl; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; R 3 is selected from the group containing of hydrogen, halogen, hydroxy, - O-C 1-4 alkyl and NR C R D; wherein R C and R D are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; Y is CH and Z is CH; alternatively Y is CH and Z is N; alternatively Y is N and Z is N; Q is selected from the group consisting of -(L 1) c -(Ring A), -(L 1) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C); c is an integer from 0 to 1; L 1 is selected from the group consisting of -CH 2 -, -CH -, -CH 2 CH 2 -,-CH 2 CH 2 CH 2 -, -CH=CH-, -CH=CH-CH 2 -, -O-, -O-CH 2 -, -C -, -C -C -,-C -CH 2 -, -C -N(R 4)-, -N(R 4)-, -N(R 4)-CH 2 -, -N(R 4)-CH 2 CH 2 -, -N(R 4)- -,-N(R 4)-C -CH 2 -, -N(R 4)-C -CH 2 -CH 2 - and -N(R 4)-C -N(R 5)-; wherein R 4 and R 5 are each independently selected from the group consisting of hydrogen and C 1-2 alkyl; (Ring A) is selected from the group consisting of 3-cyano-phenyl, 3-benzimidamide, azetidin-3-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4-isopropyl-piperazin-1-yl, piperazin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 4-amino-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 4-phenyl-piperidin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, 3-amino-pyrrolidin-1-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 6-methyl-pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4yl, 1-(amino-methyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1-(amino-ethyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1,4-diazepan-1-yl, benzimidazol-5-yl, 1-methyl-benzimidazol-6-yl, 1-methyl-benzimidazol-5-yl, benzo[c][1,2,5]oxadiazol-5-yl, 2,5-diazabicyclo[2.2.1]hept-1-yl, 2,7-diazaspiro[4,4]nonan-2-yl and octahydropyrrolo[3,4-c]pyrrol-2-yl; (Ring B) is selected from the group consisting of phenyl and 4 to 10 membered, nitrogen containing ring structure; (Ring C) is selected from the group consisting of 4 to 10 membered, nitrogen containing ring structure; wherein (Ring C) is optionally substituted with one to two substituents independently selected from the group consisting C 1 - 4 alkyl; or a pharmaceutically acceptable salt thereof